Pope's Blood Tests Show ‘Slight Improvement,' Vatican Says
Trump to Halt NY Congestion Pricing by Terminating Approval
Sorry, Kids: Disney's New York Headquarters Is for Grown-Ups
Why Barcelona Bought the Building That Symbolizes Its Housing Crisis
Child Migrant Watchdog Gutted in DOGE Cuts
Por qué Barcelona compró el edificio que simboliza su crisis inmobiliaria
Earlier in the day, the pontiff, who was admitted for treatment in Rome on Friday, met for 20 minutes with Italian Prime Minister Giorgia Meloni, who said he is 'alert and responsive.'
'We joked as always,' Meloni said in an earlier statement. 'He hasn't lost his proverbial sense of humor.'
Francis, 88, was hospitalized after what doctors called an increasingly complex health issue. The Vatican said the pope was suffering from pneumonia in both lungs — and that medical staff had altered his drug regimen to battle the infection.
Born Jorge Mario Bergoglio in Buenos Aires, Francis has been the spiritual leader of the world's Catholics since 2013. He is the first pope to hail from the Americas and the first non-European pontiff since the eighth century.
How Med Spas Conquered America
Before DeepSeek Blew Up, Chatbot Arena Announced Its Arrival
The Startup That Stepped In When the Baby Formula Supply Chain Broke
The Undocumented Workers Who Helped Build Elon Musk's Texas Gigafactory
The Unicorn Boom Is Over, and Startups Are Getting Desperate
©2025 Bloomberg L.P.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
23 minutes ago
Pregnant wife of former NBA player speaks out after surviving shark bite
Eleonora Boi, the pregnant wife of former NBA player Danilo Gallinari, is speaking out for the first time after surviving a shark bite off a beach in Puerto Rico. "I have to say, I'm traumatized," Boi told "Good Morning America." Gallinari and Boi, a sports journalist from Italy who was six months pregnant at the time, had been swimming in waist-deep water with their two young children when Boi said she was suddenly bit on the thigh. "I felt a strong pain, and my thigh was burning, but my idea was, 'Maybe it's a huge jellyfish.' But in the reality, it wasn't a jellyfish," Boi said. "I started crying and screaming and I was screaming for help in Italian," the mom of two added. Gallinari said he rushed to help. "As soon as everyone started screaming, I had my son with me. I ran towards my wife and my daughter," said the former NBA forward, who currently plays with the Vaqueros de Bayamón in Puerto Rico. The couple picked up their children and rushed to shore, where they said a woman helped put pressure on Boi's wound with a clean towel until help arrived. "'Oh, my God,' I was saying, 'I don't want to die' and 'I want that my baby is safe.' And I was crying. I was desperate, really desperate," Boi recalled. Boi and Gallinari said they are grateful to the good Samaritan who stayed by their side. "She was an angel. Danilo was with me, and she helped so much. I would like to say thank you to this woman, because I don't know her name, and I just want to say thank you to her, because she helped a lot," said Boi. Boi said she was transported to a hospital where doctors ran hours of tests to make sure the baby was OK before they decided on an operation for her. "After they gave us confirmation that the kid was OK and nothing happened to him, then they started the surgery process," Gallinari said. Boi's doctors told her they had never treated a shark bite victim but expect Boi to make a full recovery. Boi currently has weekly visits with her doctor and is due to give birth in November. Despite the good news about her physical health, Boi said the ordeal has taken a toll on her mentally. "I have to be honest, it's not easy, because when I remember, I'm still scared -- and, you know, it's difficult," Boi said. Gallinari added, "I think that the body in this situation recovers faster than the mind, and that's something that, you know, you don't have to be ashamed of or scared of."
Yahoo
25 minutes ago
- Yahoo
Causes, symptoms and how to prevent chikungunya - as cases rise in the UK
Health authorities have warned of a "worrying increase" in cases of a mosquito-borne infection in people returning to the UK from abroad. of chikungunya were reported between January and June 2025 - more than double the 27 cases reported in the same period last year, the UK Health Agency (UKHSA) said. Data released by the agency also revealed three cases of oropouche virus, marking the first time the virus has been reported in the UK. Here is everything you need to know about both viruses, from symptoms to prevention and what could be behind the surge in cases. What is chikungunya? Chikungunya is a disease caused by a virus of the same name. It was first identified following an outbreak in Tanzania in 1952. The name is derived from a word in the Tanzanian language Makonde, and means "that which bends up", owing to the joint pain it can cause. It is spread by mosquito bites, specifically from yellow fever and tiger mosquitoes, in tropical and subtropical regions. What are the symptoms? Typical symptoms include fever, muscle pain, nausea, fatigue and a rash. The UKHSA says joint pain can persist for months or even years, with up to 12% of people still experiencing discomfort three years after infection. The majority of people who become infected recover within one to two weeks without needing medical attention. Serious complications are uncommon, and only very rare cases are fatal. Babies or elderly people with other underlying illnesses are the most vulnerable. The two mosquitoes known to transmit the disease, yellow fever and tiger, are not currently found in the UK. How does oropouche virus differ? Oropouche virus is spread predominantly by midge bites rather than mosquito bites. While bites from both insects can cause red itchy lumps on the skin, mosquito bites are generally larger and more painful, while midge bites are smaller and may last longer. Symptoms can be similar to chikungunya, and include joint paint, headache, chills, nausea and high fever. The UKHSA says anyone who becomes unwell with these symptoms after travelling should seek "urgent medical advice". Where can you catch the viruses? Regular outbreaks of chikungunya occur in Africa, Asia and the Americas, with occasional smaller instances in Europe. The UKHSA said the majority of the 73 reported cases from the first six months of this year reported travelling to Sri Lanka, India and Mauritius. The cases were linked to local outbreaks in the Indian Ocean region. As of last month, there have been about 240,000 cases of chikungunya - and 90 deaths - in 16 countries, according to the European Centres for Disease Prevention and Control (ECDC). Meanwhile, all the UK cases of oropouche virus were associated with travel to Brazil. Last year, 44 cases were reported in several European countries including Spain, Italy, France, Germany, Austria, Sweden and the Netherlands, according to the ECDC. China is currently experiencing the ever documented in the country, according to Cesar Lopez-Camacho of the University of Oxford. More than 7,000 cases have been reported since June, with 90% of those concentrated in Guangdong province, which borders Hong Kong. How to prepare before travelling Dr Philip Veal, a consultant in public health at UKHSA said it is "essential" for people to take precautions against mosquito bites when travelling. "Simple steps, such as using insect repellent, covering up your skin and sleeping under insecticide-treated bed nets can greatly reduce the risk," he said. Checking the latest health advice on your destination before you travel is also recommended. The LSHTM added that people can do the following to reduce exposure to mosquito and midge bites:• Fit screens to windows and doors;• Avoid peak activity during dusk and dawn;• Get rid of any standing water where mosquitoes breed. There are also two vaccines for chikungunya approved for use in the UK: IXCHIQ, for people aged 18 to 59 and Vimkunya, for individuals 12 years and older. Both are available to buy privately from travel clinics after an assessment by a healthcare professional. Read more from Sky News: What's behind the increase in cases? The number of outbreaks of chikungunya has increased since 2000, Robert Jones, an assistant professor at the London School of Hygiene and Tropical Medicine (LSHTM) said. Mr Jones put this boom partly down to climate change and urban expansion. Dr Yang Liu, another professor at LSHTM, said the outbreak in China is not totally unexpected, but highlights the manifestation of a known risk, as yellow fever and tiger mosquitoes have been present in the area for many years.
Business Wire
17 hours ago
- Business Wire
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2025, and is pleased to provide an update on key business milestones. 'With our recently announced funding agreement in place, we are well positioned to continue advancing our lead clinical programs, CYB003 and CYB004, through multiple inflection points,' said Doug Drysdale, Chief Executive Officer of Cybin. 'Gaining European CTA approval and MHRA approval to commence EMBRACE in the UK has enabled us to expand our multinational Phase 3 PARADIGM program evaluating CYB003 for the potential adjunctive treatment of major depressive disorder. PARADIGM is a significantly larger program than the completed Phase 2 study, with anticipated combined enrollment of approximately 550 participants. Our Phase 3 studies will evaluate the potential clinical benefits of CYB003 in patients living with moderate to severe MDD, and whose symptoms are uncontrolled with existing antidepressant treatment. Our Phase 2 study evaluating CYB004 in generalized anxiety disorder is expected to complete patient enrollment this month.' 'Cybin is in a strong position to advance our programs and continue our work to deliver innovative therapies to address some of the most challenging mental health disorders we face today and is helping to build momentum across the sector - both from a clinical and regulatory perspective,' concluded Drysdale. Recent Business and Pipeline Highlights: Received European approval and MHRA approval for EMBRACE, the second Phase 3 study within the PARADIGM program evaluating CYB003 for the adjunctive treatment of MDD, on schedule. The Company has received CTA approval from the Irish Medicines Board for the EMBRACE study in Ireland, Poland, and Greece, as well as approval from the MHRA. EMBRACE is a 12-week, randomized, double-blind, placebo-controlled study in 330 participants with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but with inadequate response. EMBRACE will evaluate two doses of CYB003 (8 mg, 16 mg) three weeks apart, compared to an inactive placebo. The primary endpoint is change in depressive symptoms as measured by the change in MADRS from baseline six weeks after the first dose. Making strong progress on CYB003 development through the APPROACH and EXTEND studies. Dosing is currently ongoing in the first pivotal study, APPROACH, which is expected to enroll 220 patients across 45 U.S. clinical sites. We are pleased to report that patient rollovers continue into EXTEND, the long-term extension study. Clinical Program Summary CYB003: Deuterated psilocin program Phase 3 PARADIGM program is underway, with topline data from first pivotal study, APPROACH, expected in 2026 1. CYB003 program accomplishments: Received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD. A completed Phase 2 study of CYB003 in MDD demonstrated durability of effect at 12 months: 100% of participants receiving two doses of 16 mg were responders. 71% of participants receiving two doses of 16 mg were in remission. Mean change from baseline in MADRS was approximately -23 points after two 16 mg doses. CYB004: Deuterated dimethyltryptamine program The Phase 2 CYB004 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with generalized anxiety disorder, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. Patient enrollment is expected to be completed this month 1. Change in Presentation Currency Effective April 1, 2025, the Company changed its presentation currency from the Canadian dollar to the United States dollar (' USD '). The change in presentation currency was made to better reflect the Company's operations, align with the currency in which the majority of cash-based expenses are denominated, and improve comparability of its financial results with other publicly traded businesses in the industry. As a result, all amounts presented in this press release are in USD unless otherwise stated. First-Quarter Financial Highlights Cash totaled $118.7 million as of June 30, 2025. Net loss was $24.6 million for the quarter ended June 30, 2025, compared to a net loss of $10.8 million in the same period last year. Cash-based operating expenses consisting of research, general, and administrative costs totaled $23.9 million for the quarter ended June 30, 2025, compared to $11.9 million, in the same period last year. Cash flows used in operating activities were $29.5 million for the quarter ended June 30, 2025, compared to $19.9 million in the same period last year. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Note: There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia; the Company's expectation to enroll 220 participants at approximately 45 clinical sites across the United States for the APPROACH study; the Company's expectation to complete enrollment in CYB004 Phase 2 study in August 2025; the Company's expectation to receive topline data from APPROACH in 2026; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2025, and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
